Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
CAVADEXA , ABADINE, ABALAMID HETERO , BACAMID, LAMAVIR 600/300 (Hetero Australia Pty Ltd)
Product name
CAVADEXA , ABADINE, ABALAMID HETERO , BACAMID, LAMAVIR 600/300
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
197 (255 working days)
Active ingredients
Lamivudine, Abacavir sulfate
Registration type
New generic medicine
Indication
CAVADEXA, ABADINE, ABALAMID HETERO , BACAMID, LAMAVIR 600/300 tablets are a combination of two nucleoside analogues (abacavir and lamivudine).
CAVADEXA, ABADINE, ABALAMID HETERO , BACAMID, LAMAVIR 600/300 is indicated in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infection in adults and adolescents from 12 years of age.